4/A//SEC Filing
Hoekman John 4/A
Accession 0001209191-21-038665
CIK 0001445499other
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 4:57 PM ET
Size
7.8 KB
Accession
0001209191-21-038665
Insider Transaction Report
Form 4/AAmended
Hoekman John
Chief Scientific Officer
Transactions
- Conversion
Common Stock
2021-04-27+4,253→ 108,496 total - Conversion
Series A-2 Preferred Stock
2021-04-27−69,657→ 0 total→ Common Stock (4,253 underlying)
Footnotes (2)
- [F1]This amended Form 4 is being filed solely to correct an inadvertent error in the number of shares of common stock acquired in connection with the conversion of shares of Series A-2 Preferred Stock held by the reporting person from 4,523 shares to 4,253 shares.
- [F2]The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
Documents
Issuer
IMPEL NEUROPHARMA INC
CIK 0001445499
Entity typeother
Related Parties
1- filerCIK 0001855676
Filing Metadata
- Form type
- 4/A
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 4:57 PM ET
- Size
- 7.8 KB